

Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease

Authors:

Martin J. Dahl^{*1,2}, Mara Mather², Markus Werkle-Bergner¹, Briana L. Kennedy^{2,3}, Samuel Guzman⁴, Kyle Hurth⁴, Carol A. Miller⁴, Yuchuan Qiao⁵, Yonggang Shi⁵, Helena C. Chui⁶, & John M. Ringman⁶

Affiliations:

¹Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany

²Davis School of Gerontology, University of Southern California, 90089 Los Angeles, CA, USA

³School of Psychological Science, University of Western Australia, Perth, Australia

⁴Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁵Laboratory of Neuro Imaging (LONI), USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁶Department of Neurology, Keck School of Medicine, University of Southern California, 90033 Los Angeles, CA, USA

*** Corresponding author:**

MJD (dahl@mpib-berlin.mpg.de)

1 **Abstract**

2 Abnormally phosphorylated tau, an indicator of Alzheimer's disease, accumulates in the first
3 decades of life in the locus coeruleus (LC), the brain's main norepinephrine supply. However,
4 technical challenges in reliable in-vivo assessments have impeded research into the role of the LC in
5 Alzheimer's disease.

6 We studied participants with or known to be at-risk for mutations in genes causing autosomal-
7 dominant Alzheimer's disease (ADAD) of early onset, providing a unique window into the
8 pathogenesis of Alzheimer's largely disentangled from age-related factors. Using high-resolution MRI
9 and tau PET, we revealed lower rostral LC integrity in symptomatic participants. LC integrity was
10 associated with individual differences in tau burden and memory decline. Post-mortem analyses in a
11 separate set of carriers of the same mutation confirmed substantial neuronal loss in the LC.

12 Our findings link LC degeneration to tau burden and memory in Alzheimer's and highlight a
13 role of the noradrenergic system in this neurodegenerative disease.

14 *Keywords:* Locus coeruleus; autosomal-dominant Alzheimer's disease; norepinephrine; tau
15 pathology; neurodegeneration; A431E

16 **Introduction**

17 Alzheimer's disease (AD) is presently an incurable neurodegenerative disease leading
18 to dementia with the number of worldwide cases predicted to triple over the next thirty years
19 (Alzheimer's Disease International, 2019; Canter, Penney, & Tsai, 2016; World Health
20 Organization, 2004). Post-mortem studies indicate that abnormally phosphorylated tau, an
21 indicator of AD, begins to appear early in life in the locus coeruleus (LC), the primary source
22 of cortical norepinephrine (Braak, Thal, Ghebremedhin, & Del Tredici, 2011; Ehrenberg et al.,
23 2017; Poe et al., 2020; Stratmann et al., 2016; Theofilas, Dunlop, Heinsen, & Grinberg,
24 2015). With increasing age, abnormal tau appears in a characteristic topographical sequence
25 in noradrenergic projection targets like the mediotemporal lobe (referred to as Braak stages, a
26 classification system of the progression of tau spread; Braak et al., 2011; Chalermphanupap,
27 Weinshenker, & Rorabaugh, 2017; Stratmann et al., 2016). Specifically, using an animal
28 model, Gosh and colleagues demonstrated that injecting hyperphosphorylated human tau into
29 the rodent LC leads to its slow spread to other brainstem nuclei and eventually to cortical
30 regions (Ghosh et al., 2019).

31 Tau deposition is strongly linked to both neural and cognitive decline in Alzheimer's
32 (Hanseuw et al., 2019; Jagust, 2018; La Joie et al., 2020). Tau burden in the LC increases
33 linearly with the progression of Braak stages while noradrenergic neurons first decrease in
34 size and then degenerate (Ehrenberg et al., 2017; Kelly et al., 2017; Theofilas et al., 2017).
35 Indeed, a meta-analysis of twenty-four post-mortem investigations revealed substantial cell
36 loss in the LC of Alzheimer's patients relative to controls (mean $d = 2.28$; 95 % CI = 2.06–
37 2.51; Lyness, Zarow, & Chui, 2003), and reduced neuron counts are evident already at
38 prodromal stages of the disease (Arendt, Brückner, Morawski, Jäger, & Gertz, 2015; Kelly et
39 al., 2017). Topographically, noradrenergic neurodegeneration is most pronounced in rostral
40 and middle segments of the nucleus that project to the hippocampus and other memory-
41 relevant areas (Ehrenberg et al., 2017; Lyness et al., 2003). LC degeneration, however, does

42 not only constitute a consequence of Alzheimer's pathology but also may contribute to its
43 disease development (Marien, Colpaert, & Rosenquist, 2004; Mather & Harley, 2016; Satoh
44 & Iijima, 2019; Weinshenker, 2018). Studies with genetically modified animals indicate that
45 abnormally phosphorylated tau in the LC leads to dysfunctional noradrenergic
46 neuromodulation in memory-relevant brain areas (Ghosh et al., 2019; Rorabaugh et al., 2017;
47 Weinshenker, 2018) and that tau pathology and LC degeneration synergistically aggravate
48 neural and behavioral deterioration (Chalermplanupap et al., 2018; also see Jacobs,
49 Riphagen, Ramakers, & Verhey, 2019). Specifically, experimentally decreased norepinephrine
50 levels have been associated with increased tau and amyloid- β deposition, another hallmark of
51 AD (Chalermplanupap et al., 2018; Heneka et al., 2010). Insights into the role of
52 noradrenergic neurodegeneration in the progression of AD are thus of high clinical
53 significance (Grinberg & Heinsen, 2017), yet in-vivo human data are scarce.

54 Studies in humans have been impeded by methodological challenges in non-invasive
55 assessments of the LC due to its small size and its location deep within the brainstem (for
56 discussions, see Astafiev, Snyder, Shulman, & Corbetta, 2010; Keren, Lozar, Harris, Morgan,
57 & Eckert, 2009). Advances in high-resolution brainstem magnetic resonance imaging (MRI)
58 may help the field overcome these hurdles (Betts, Kirilina, et al., 2019; Liu et al., 2017; Sun
59 et al., 2020). Over the last fifteen years, several MRI sequences have been developed that
60 reveal the LC as a hyperintense cluster of voxels bordering the fourth ventricle (e.g., Betts,
61 Cardenas-Blanco, Kanowski, Jessen, & Düzel, 2017; Nakane, Nihashi, Kawai, & Naganawa,
62 2008; Priovoulos et al., 2017; Sasaki et al., 2006). Keren and colleagues (2015) validated a
63 MR-based LC imaging sequence by first scanning human post-mortem samples at ultra-high
64 field strength and afterwards performing histological analyses of the same samples. They
65 demonstrated that the hyperintensities observed on MRI scans closely co-localize with
66 noradrenergic cells as identified by tyrosine hydroxylase (the rate-limiting enzyme of
67 catecholamine synthesis) staining, opening the door for non-invasive LC assessments (Keren

68 et al., 2015; also see Cassidy et al., 2019 for a postmortem validation in dopaminergic
69 structures and Betts, Kirilina, et al., 2019 for a discussion of potential contrast mechanisms).

70 Probing the utility of LC MRI to detect pathology-related changes in the noradrenergic
71 system in vivo, several studies compared patients diagnosed with AD to healthy controls
72 (Betts, Cardenas-Blanco, et al., 2019; Dordevic et al., 2017; Miyoshi et al., 2013; Takahashi
73 et al., 2015). In general agreement with earlier post-mortem investigations (Lyness et al.,
74 2003), the majority of studies observed lower LC MR-intensity, a proxy for the density of
75 noradrenergic cells (Keren et al., 2015), in the patient groups (but see Miyoshi et al., 2013).
76 However, all of these studies investigated the by far most common, late-onset type of AD
77 (>65 years; LOAD). LOAD is considered a heterogeneous, age-related disease that
78 encompasses not only tau and amyloid pathology but also the aggregation of other proteins
79 such as α -synuclein, the effects of cerebrovascular ischemia, and other processes (Jagust,
80 2018; Van Cauwenberghe, Van Broeckhoven, & Sleegers, 2016). Given that large lifespan
81 studies suggest spatially confined age differences in LC integrity in healthy older adults (Dahl
82 et al., 2019; Liu et al., 2019), unambiguously distinguishing disease- from age-related
83 changes on this basis is challenging (Lindenberger, von Oertzen, Ghisletta, & Hertzog, 2011).
84 Focusing instead on forms of AD that begin early in life allows the possibility of
85 distinguishing age- from disease-related changes (cf. Jacobs, Becker, et al., 2019).

86 Autosomal dominant Alzheimer's (ADAD) is a rare inherited disease caused by
87 mutations in genes associated with the generation or accumulation of amyloid- β (Bertram,
88 Lill, & Tanzi, 2010; Tanzi & Bertram, 2005; Van Cauwenberghe et al., 2016). In contrast to
89 LOAD, it constitutes a relatively "pure" tau and amyloid pathology in which cerebrovascular-
90 or other age-related neuropathological changes are absent (Jagust, 2018; Ringman et al.,
91 2016). In ADAD, symptoms develop early in life with a relatively predictable age at onset
92 (Ryman et al., 2014), thus providing a unique window into the pathogenesis of Alzheimer's
93 (Bateman et al., 2012; Ringman, 2005). Whether or not there is MR-identifiable LC

94 degeneration also in patients diagnosed with Alzheimer's dementia early in life is still an open
95 question. Importantly, answering this question could help shed light on whether LC
96 involvement is a core feature of AD or whether it should be considered more indicative of a
97 non-Alzheimer's process generally associated with aging, such as the process outlined in the
98 "primary age-related tauopathy" framework (Crary et al., 2014).

99 While previous post-mortem research suggests a topographical pattern of
100 noradrenergic neurodegeneration within the LC in LOAD (Ehrenberg et al., 2017; Lyness et
101 al., 2003), most current in-vivo (MRI) studies lack the spatial specificity to draw comparable
102 conclusions. That is, they report disease-related differences in MR-indexed LC integrity
103 (Dordevic et al., 2017; Takahashi et al., 2015) without exploring potential topographical
104 patterns therein, precluding direct comparisons (but see Betts, Cardenas-Blanco, et al., 2019).
105 Investigations in healthy participants successfully applied LC MRI to map the spatial extent
106 of the central noradrenergic nucleus in standard space (Betts et al., 2017; Dahl et al., 2019;
107 Keren et al., 2009; Liu et al., 2019; Tona et al., 2017; Ye et al., 2021), paving the way for
108 topographical cross-study comparisons. However, estimates of locus coeruleus' dimensions
109 and localizations show a sizeable variance across publications (range of agreement: 48–94 %;
110 cf. Dahl et al., 2019; Liu et al., 2019; Ye et al., 2021; or even 1–40 % using a different
111 methodology, Mäki-Marttunen & Espeseth, 2020). Such lack of consensus considerably limits
112 the replicability of findings and impedes scientific progress.

113 Thus, the present study pursued two main goals: First, we aimed at improving the
114 reliability and validity of MR-based LC detection. Leveraging a meta-analytical approach, we
115 aggregated across previously published maps of the LC (Betts et al., 2017; Dahl et al., 2019;
116 Keren et al., 2009; Liu et al., 2019; Tona et al., 2017; Ye et al., 2021) to derive a biologically
117 plausible volume of interest (meta mask) that shows high agreement across investigations.
118 Second, we aimed at determining whether MR-indexed LC integrity can serve as marker for
119 noradrenergic degeneration in early-onset ADAD. To this end, we applied the newly

120 generated meta mask to an independent clinical sample to semi-automatically extract MR-
121 indexed LC integrity across the rostrocaudal extent of the nucleus (cf. Dahl et al., 2019). We
122 specifically focused on a sample of participants with or known to be at-risk for rare mutations
123 in genes causing ADAD (Presenilin-1 protein gene [*PSENI*]; Amyloid- β Precursor Protein
124 gene [*APP*]; Goate et al., 1991; Murrell et al., 2006; Yescas et al., 2006). In addition, using an
125 independent sample of banked post-mortem neuropathological specimens, we characterized
126 changes occurring in the LC in persons dying with the A431E mutation in *PSENI* relative to
127 controls. We hypothesized that middle to rostral MR-indexed LC integrity would be lower in
128 living symptomatic participants relative to healthy matched controls, corroborating earlier
129 post-mortem findings (in LOAD; Lyness et al., 2003). Similarly, post-mortem LC specimens
130 were hypothesized to show signs of neurodegeneration in ADAD relative to controls. Finally,
131 we predicted MR-indexed LC integrity would be associated with cortical tau burden
132 (Chalermphanupap et al., 2018), as assessed using positron emission tomography (PET), and
133 attention and memory performance (Dahl et al., 2019; Elman et al., 2020; Liu et al., 2020).


134 **Results**

135 **Aggregating across published locus coeruleus maps yields high confidence meta mask**

136 Previously published masks of the LC (Betts et al., 2017; Dahl et al., 2019; Keren et
137 al., 2009; Liu et al., 2019; Tona et al., 2017; Ye et al., 2021) were averaged voxel-per-voxel
138 to generate an unthresholded overlay ($LC_{aggregate}$). The $LC_{aggregate}$ demonstrated a core of
139 voxels that, across publications, were consistently judged to belong to the LC (see dark-blue
140 areas in Figure 1), surrounded by a cloud of ambiguous, low-agreement voxels (see yellow
141 areas in Figure 1). Topographically, consensus was lowest in most rostral and caudal areas
142 (see inlay in Figure 1).

143 Pruning low-agreement voxels yielded a high-confidence LC volume of interest
144 ($LC_{metaMask}$; available for download via: osf.io/sf2ky/) that matches the dimensions reported in
145 post-mortem investigations (Fernandes et al., 2012) and allows assessment of the accuracy of
146 previously published masks.

147



148

149 **Figure 1.** Aggregating across published locus coeruleus (LC) maps yields high confidence meta mask.
150 **Left.** Unthresholded voxel-by-voxel average across published LC masks. Areas with voxels that are
151 consistently judged to belong to the LC are shown in dark blue while low agreement areas are shown
152 in yellow. **Inlay.** Agreement across masks (averaged across voxels in-plane) is lowest in most rostral
153 and caudal regions. **Middle.** Pruning low agreement areas isolates a core of high confidence voxels.
154 **Right.** Smoothing and filtering the thresholded overlay yields a biologically plausible LC volume of
155 interest (rostroro-caudal extent of 14 mm; volume of 74 mm³ [592 voxels]), corresponding well with
156 earlier post-mortem reports (Fernandes et al., 2012). Sl. #, slice number in MNI 152 lin (0.5 mm)
157 space; The LC meta mask is available for download via: osf.io/sf2ky/.


158

159 **Accuracy of previously published locus coeruleus masks**

160 Once a high-confidence LC volume of interest ($LC_{metaMask}$) was generated, published
161 masks were evaluated regarding their specificity and sensitivity. That is, we assessed (1) how
162 many voxels judged by a given mask as belonging to the locus coeruleus were part of the
163 $LC_{metaMask}$, and (2) what percentage of the $LC_{metaMask}$ was included in each individual mask.
164 The mean across specificity and sensitivity was taken as accuracy measure to rank the masks
165 (see Figure 2).

166 The masks that were computed based on the largest samples (cf. Table 1; Dahl et al.,
167 2019; Liu et al., 2019) demonstrated the highest accuracy. Concerning specificity and
168 sensitivity, the two masks appeared almost as mirror images. That is, the volume of interest
169 published by Liu and colleagues evinced a high sensitivity at the cost of a relatively lower
170 specificity (i.e., it included also non-LC voxels), while the situation was reversed for the mask
171 by Dahl and colleagues (in line with it mapping peak LC coordinates; Dahl et al., 2019).
172 Notably, the two masks themselves show a high agreement (94 %; Liu et al., 2019). Ye and
173 colleagues tested a smaller sample, albeit with a higher field strength (7 T) to generate their
174 volume of interest which appears to strike a balance between sensitivity and specificity. None
175 of the tested masks, however, exceeded an accuracy rating of $\frac{2}{3}$, indicating that, by
176 aggregating across publications, the $LC_{metaMask}$ forms a volume of interest that conveys
177 valuable information (i.e., is not redundant with previous masks).

178



179


180 **Figure 2.** Accuracy of previously published locus coeruleus (LC) masks. Binarized masks in standard
181 space (MNI 152, lin; top row) are ranked based on their accuracy (mean across specificity and
182 sensitivity). Specificity expresses the percentage of a given mask that is included in the *LCmetaMask*
183 whereas sensitivity denotes the percentage of the *LCmetaMask* that is part of each mask. For access to
184 the individual masks, please refer to Table 1. Note that the relative position of the individual masks
185 (top row) corresponds to their position in MNI 152 linear space; x/y/z axes are not displayed for
186 clarity.

187

188 **Locus coeruleus meta mask captures high intensity voxels in independent clinical sample**

189 We aligned and pooled across brainstem scans of participants with or known to be at-
190 risk for ADAD mutations (cf. Dahl et al., 2019). On the group level, we observed a cluster of
191 hyperintense voxels bordering the lateral floor of the fourth ventricle (Betts, Kirilina, et al.,
192 2019). This LC-related hyperintensity was accurately captured by the $LC_{metaMask}$ while
193 excluding more medial, non-LC related high intensity voxels (see Figure 3). Taken together,
194 this indicates that the $LC_{metaMask}$ can be applied to independent datasets to reliably extract MR-
195 indexed integrity across the rostrocaudal axis.

196




197

198 **Figure 3.** LC-related hyperintensity is accurately captured by meta mask. **Upper row.** Axial and
199 coronal view of brainstem template overlaid on standard MNI brain. **Inlays.** The area surrounding the
200 fourth ventricle is depicted with (1) a greyscale colormap and (2) a black-to-white-to-red colormap to
201 highlight hyperintense areas. (3) LC-related hyperintensities closely overlap with the LC meta mask
202 (blue overlay; white overlay, pontine reference region). **Lower row.** 3-D representation of (a) the LC
203 meta mask, (b) above-average intensity voxels, and (c) their overlap from a front and back view. Sl. #,
204 slice number in MNI 152 linear (0.5 mm) space; LC, locus coeruleus. Right hemisphere is plotted on
205 the left.

206 **Lower MR-indexed locus coeruleus integrity in autosomal-dominant Alzheimer's disease**

207 Comparing LC intensity ratios—an in-vivo proxy for the integrity for the structure
208 (Keren et al., 2015)—across cognitively normal and symptomatic participants, we observed
209 reliably lower intensity in the patient group (Wilcoxon rank sum test, $Z = -2.177$; $p = 0.03$;
210 see Figure 4). This difference was most pronounced in middle–rostral segments of the nucleus
211 that project to the mediotemporal lobe (Wilcoxon rank sum test of group differences in rostral
212 vs. caudal segment; $Z = -2.816$; $p = 0.005$; see Figure 4). Among carriers of ADAD
213 mutations, closer proximity to the mutation-specific median age of dementia diagnosis—
214 termed adjusted age—was associated with lower LC ratios (mean correlation coefficient
215 across 1,000,000 bootstraps: $\rho = -0.726$; $p = 0.047$; see Figure 4). Taken together,
216 corroborating earlier post-mortem work (in LOAD; Lyness et al., 2003), we observed lower
217 MR-indexed LC integrity in middle–rostral segments of the nucleus, potentially indicating
218 noradrenergic neurodegeneration.

219




221 **Figure 4.** Lower LC intensity ratios in autosomal-dominant Alzheimer's disease (ADAD). **a.**
222 Symptomatic participants show lower overall LC intensity ratios relative to cognitively
223 normal controls ($Z = -2.177$; $p = 0.03$). **b.** Group differences are most pronounced in middle–
224 rostral segments of the LC (plotted on the y-axis; $Z = -2.816$; $p = 0.005$; shaded areas indicate
225 ± 1 standard error of the mean [SEM]). **c.** Closer proximity to the mutation-specific median
226 age of dementia diagnosis (adjusted age) is associated with lower overall LC ratios (mean
227 correlation coefficient across 1,000,000 bootstraps: $\rho = -0.726$; $p = 0.047$). LC, locus
228 coeruleus; Cog. normal, cognitively unimpaired participants.

229 **MR-indexed locus coeruleus integrity is associated with cortical tau burden**

230 Previous animal research suggests that noradrenergic neurodegeneration may
231 exacerbate neural decline and contribute to Alzheimer's pathogenesis (Chalermphanupap et
232 al., 2018; Rorabaugh et al., 2017). Thus, we next tested whether LC intensity would be
233 associated with cortical tau burden, a hallmark of AD.

234 Across cortical regions (Desikan et al., 2006), symptomatic participants demonstrated
235 higher flortaucipir SUVR (see Figure 5). Importantly, leveraging a multivariate statistical
236 approach (partial least squares correlation [PLSC]; Krishnan et al., 2011), we revealed a
237 topographical pattern of LC-related tau pathology ($p = 0.037$; see Figure 5). That is, we
238 extracted a latent variable (latent PLS score) that optimally captures the multivariate
239 association between participants' LC intensity and regional tau burden ($r = 0.54$ [95 %
240 confidence interval (CI): 0.167, 0.806]; lower LC intensity was associated with higher
241 flortaucipir SUVR). Especially tau pathology in occipito-temporo-parietal regions contributed
242 to this latent variable, as indicated by reliable bootstrap ratios (BSR; < -3 ; see Figure 5; BSR
243 can be interpreted akin to Z-values; please note that we opted for a conservative threshold [$-$
244 3] due to the large number of cortical ROI). In sum, in line with research in genetically
245 modified animals (Chalermphanupap et al., 2018; Rorabaugh et al., 2017), we observed a
246 prominent association between in-vivo proxies of LC integrity and tau pathology.

247



248

249 **Figure 5.** Lower LC intensity is associated with tau burden in posterior brain regions. **a.**
250 Symptomatic participants show higher flortaucipir standardized uptake value ratios (SUVR)
251 across most cortical regions relative to cognitively normal controls (missing PET data for two
252 participants [dark blue bars]). **b.** Contribution of individual cortical regions of interest to a
253 partial least squares (PLS) latent variable indexing LC-related tau pathology (Bootstrap ratios
254 < -3 are considered reliable). **c.** Scatter plot depicting the relation between latent PLS scores
255 and LC intensity ($p = 0.037$; $r = 0.54$ [95 % CI: 0.167, 0.806]). LC, locus coeruleus; ADAD,
256 autosomal-dominant Alzheimer's disease.

257

258

259 MR-indexed locus coeruleus integrity is associated with cognitive deficits

260

Finally, we set out to test the behavioral relevance of our in-vivo proxy of LC

261

integrity. Norepinephrine release from the LC is strongly implicated in the modulation of

262

attentional and mnemonic processing (Berridge & Waterhouse, 2003; Dahl, Mather, Sander,

263

& Werkle-Bergner, 2020; Lee et al., 2018; Sara, 2009). Accordingly, recent imaging studies

264

reported positive associations between LC intensity and cognition in healthy aging (Dahl et

265

al., 2019; Hämmerer et al., 2018; Liu et al., 2020). However, whether this relation extends to

266

ADAD of young onset is currently unknown.

267

Across a range of cognitive tasks, we detected worse cognitive abilities and higher

268

dementia symptoms in the ADAD group relative to controls (see Figure 6). Reliable group

269

differences (Wilcoxon rank sum test; $Z < -1.96$ | $Z > 1.96$) were observed for screening

270


instruments (the Montreal Cognitive Assessment [MoCA, Nasreddine et al., 2005]; the

271

Cognitive Abilities Screening Instrument [CASI; Teng et al., 1994], and the Washington

272 University Clinical Dementia Rating Scale [CDR; measure: sum of boxes; cf. O'Bryant et al.,
273 2008]). In addition, symptomatic participants performed significantly worse on the Spanish
274 English Verbal Learning Test (SEVLT; measures: average performance over learning trials
275 and delayed recall; González, Mungas, & Haan, 2002), in line with reports of verbal learning
276 tests to convey information about participants' current and future cognitive status (Albert,
277 Moss, Tanzi, & Jones, 2001; Belleville, Fouquet, Hudon, Zomahoun, & Croteau, 2017;
278 Moradi, Hallikainen, Hänninen, & Tohka, 2017; Schoenberg et al., 2006).

279 We applied a partial least squares correlation (PLSC) to isolate the pattern of cognitive
280 impairment reliably linked to MR-indexed LC integrity. Our analyses isolated a single latent
281 variable ($p = 0.016$) that optimally expresses the multivariate association between
282 participants' LC intensity and cognitive performance ($r = 0.728$ [95 % CI: 0.408, 0.888]). All
283 cognitive tasks that were sensitive to distinguish symptomatic from cognitively normal
284 participants contributed reliably to this latent variable (bootstrap ratios [BSR] < -1.96 | BSR >
285 1.96; see Figure 6). To conclude, across a range of neuropsychological tests, higher MR-
286 indexed LC integrity was observed in participants with unimpaired cognitive performance.



287


288 **Figure 6.** Lower LC intensity is associated with cognitive deficits. **a.** Symptomatic
289 participants show lower cognitive performance as indicated from screening instruments for
290 mild cognitive impairment and dementia (Clinical Dementia Rating Scale, sum of boxes
291 [CDR]; Cognitive Abilities Screening Instrument [CASI]; Montreal Cognitive Assessment
292 [MoCA]) as well as the Spanish English Verbal learning task (SEVLT). **b.** Contribution of
293 individual neuropsychological tests to a partial least squares (PLS) latent variable indexing
294 LC-related cognitive deficits (Bootstrap ratios < -1.96 and > 1.96 are considered reliable). **c.**
295 Scatter plot depicting the relation between latent PLS scores and LC intensity ($p = 0.016$; $r =$
296 0.728 [95 % CI: 0.408, 0.888]). LC, locus coeruleus; ADAD, autosomal-dominant
297 Alzheimer's disease. For references to the cognitive tasks, please refer to the main text.

298
299

300 Neuropathological findings in the locus coeruleus

301 Descriptions of the neuropathological changes occurring in the brainstem in ADAD
302 are scarce. To characterize the pathology underlying the LC signal on MRI in ADAD, LC
303 histopathology was compared between four carriers of the A431E mutation in *PSEN1* (aged
304 39–59 years, 2 ♀), including one person homozygous for the A431E mutation (Parker et al.,
305 2019), and five neurologically normal controls (aged 37–58 years, 2 ♀). All A431E mutation
306 carriers demonstrated severe loss of LC neurons and background astrogliosis by GFAP
307 relative to controls. The remaining LC neurons from the A431E mutant carriers demonstrated
308 a severe loss of neuromelanin and reactivity (see Figure 7). AT8 staining showed neuritic
309 changes in all A431E mutation carriers with three of four showing neurofibrillary tangle
310 formation. On staining with 4G8, three mutation carriers showed diffuse extracellular neuritic
311 and coarse grained plaques. Two of five controls showed rare coarse grained extracellular

312 plaques. Alpha synuclein staining did not reveal any Lewy body pathology in any samples.
313 Immunostaining using antibodies against 4-repeat tau (RD4) and 3-repeat-tau (RD3) showed
314 positivity for both isoforms.



315

316 **Figure 7.** Neuropathological findings in the locus coeruleus of a 45–50 year old woman
317 heterozygous for the A431E mutation in *PSEN1*, a 35–40 year old man homozygous for the
318 A431E mutation in *PSEN1*, and a normal control (45–50 year old). Hematoxylin and Eosin
319 (H&E) staining shows profound drop-out of neurons in the *PSEN1* mutation carriers
320 compared to control. Neurons within carriers lack neuromelanin and show loss of pigment;
321 whereas, neurons within control show robust pigmentation and neuromelanin expression.
322 Immunostained slides with anti-tau (AT8) antibodies using red chromagen demonstrate
323 neurofibrillary tangles within neurons and the presence of many tau positive threads in
324 *PSEN1* mutation carriers with only a very rare single neurofibrillary tangle observed in
325 normal control (lower portion of image).

326 **Discussion**

327 Animal and post-mortem research indicates that the brain's noradrenergic system plays
328 a central role in the pathogenesis of Alzheimer's disease (Braak et al., 2011; Weinschenker,
329 2018). In vivo investigations, however, have long been hindered by challenges in reliable
330 non-invasive LC assessments (Astafiev et al., 2010; Keren et al., 2009). While initial
331 intriguing in vivo studies in late-onset Alzheimer's are underway (LOAD; e.g., Betts,
332 Cardenas-Blanco, et al., 2019; Jessen et al., 2018), unequivocally distinguishing age- from
333 disease-related LC alterations is difficult on this basis (Dahl et al., 2019; Liu et al., 2019).
334 Focusing instead on types of dementia developing earlier in life provides a unique window
335 into the mechanisms driving Alzheimer's development (ADAD; Bateman et al., 2012; Jacobs,
336 Becker, et al., 2019; Ringman, 2005).

337 Leveraging a meta-analytical approach, we first synthesized LC localizations and
338 dimensions across previously published studies to improve the reliability and validity of MR-
339 based LC detection. In a second step, we applied this newly generated volume of interest to
340 determine whether MR-indexed LC integrity can serve as marker for noradrenergic
341 degeneration in ADAD and verified this pathology using post-mortem samples.

342 Our analyses isolated a cluster of high-confidence voxels that (1) is consistently
343 identified as LC across published studies and (2) corresponds well to post-mortem reports
344 (Fernandes et al., 2012). Next, exploiting this refined spatial characterization we semi-
345 automatically extracted intensity data in an independent sample of participants with or known
346 to be at-risk for mutations in genes associated with ADAD. We revealed lower MR-indexed
347 LC integrity in symptomatic mutation carriers. Group differences were most pronounced in
348 middle to rostral segments of the LC (Ehrenberg et al., 2017; Lyness et al., 2003) and scaled
349 with proximity to the mutation-specific median age of dementia diagnosis (Ryman et al.,
350 2014). Beyond that, lower overall LC intensity was linked to higher tau burden in posterior
351 brain regions (Chalermphanupap et al., 2018) and worse cognitive performance across

352 several neuropsychological tests (Dahl et al., 2019; Liu et al., 2020). Taken together, our
353 finding of diminished LC integrity in ADAD suggests a prominent role of the noradrenergic
354 system in this neurodegenerative disease.

355

356 **Aggregating across published locus coeruleus maps yields high confidence meta mask**

357 Imaging of small brainstem structures that are not visible using conventional MR
358 sequences is notoriously challenging (for discussions, see Astafiev et al., 2010; Keren et al.,
359 2009) and warrants a close alignment of individual scans (for recommendations, see Betts,
360 Kirilina, et al., 2019; Liu et al., 2017). Here we used Advanced Normalization Tools (ANTs;
361 Avants et al., 2011, 2009) for brainstem normalization. ANTs is becoming increasingly
362 recognized as a powerful tool for accurate coregistrations – it has won several internationally
363 recognized medical image processing challenges (e.g., Klein et al., 2009 for a full list see
364 github.com/ANTsX/ANTs) and was used in all of the currently best ranked LC mapping
365 studies (3/3, [relative to 1/3 of the remaining studies]; Dahl et al., 2019; Liu et al., 2019; Ye et
366 al., 2021).

367 Besides normalization, LC mapping studies employing larger sample sizes and a
368 higher MR-field strength evinced a higher accuracy, as indicated by spatial congruence with
369 the meta mask (Dahl et al., 2019; Liu et al., 2019; Ye et al., 2021). We hope that by sharing an
370 unbiased, biologically-plausible LC volume of interest that is based on more than 1,000
371 participants and all commonly used sequence types (FSE, MT, FLASH; see Table 1) we assist
372 future functional and structural imaging studies in classifying brainstem effects (this LC meta
373 mask is available for download via osf.io/sf2ky/).

374

375 **Lower MR-indexed locus coeruleus integrity in autosomal-dominant Alzheimer's disease**

376 Applying the newly generated LC meta mask to an independent clinical sample, we
377 demonstrate its utility for accurately extracting intensity information across the rostrocaudal

378 extent of the nucleus. We observed lower middle–rostral LC intensity in symptomatic carriers
379 of ADAD-causing mutations. This finding is consistent with post-mortem reports of
380 substantial noradrenergic neurodegeneration in LOAD (Lyness et al., 2003). Some previous
381 post-mortem studies in ADAD also noted disproportionate depigmentation and neuronal loss
382 in the LC (Janssen et al., 2000; Snider et al., 2005) which we verified in four persons dying
383 with the A431E mutation in *PSENI*. In vivo imaging studies are in general agreement with the
384 histological findings and indicate lower LC contrast in LOAD patients (Betts, Cardenas-
385 Blanco, et al., 2019; Dordevic et al., 2017; Takahashi et al., 2015). To date there is only a
386 single imaging study focusing on early-onset Alzheimer's (ADAD; Jacobs, Becker, et al.,
387 2019), albeit in non-symptomatic mutation carriers (i.e., at a preclinical stage). Our
388 observation that LC intensity scaled with proximity of dementia onset (adjusted age) across
389 non-symptomatic and symptomatic mutation carriers matches a negative age association in
390 mutation carriers reported by Jacobs and colleagues (2019) and might indicate a progressive
391 deterioration. In conjunction with prior post-mortem validations of LC MRI (Keren et al.,
392 2015; Cassidy et al., 2019) and decreased cell counts in LOAD (Lyness et al., 2003), our post-
393 mortem validation of decreased cell counts in the LC in ADAD are indicative of
394 noradrenergic neurodegeneration in ADAD.

395

396 **MR-indexed locus coeruleus integrity is associated with cortical tau burden**

397 Leveraging a multivariate statistical approach, we further revealed a pattern of LC-
398 related tau pathology that was most pronounced in posterior brain regions (cf. Jacobs, Becker,
399 et al., 2019). This observation supports the notion that loss of noradrenergic neurons may
400 exacerbate the severity of other Alzheimer's hallmarks, like tau pathology (Chalermpanupap
401 et al., 2018). The LC is one of the first brain regions in which aberrant tau can be detected at
402 relatively early ages (i.e., the first decades of life; Braak et al., 2011). The accumulation of
403 abnormal tau has been hypothesized to shift noradrenergic cells to a mode of hyperactivity

404 which in turn promotes tau release and spread along LC' widespread axonal pathways
405 (Chalermphanupap et al., 2017; Weinshenker, 2018). While tau gradually propagates through
406 cortical regions (categorized as Braak stages), noradrenergic neurons first shrink in size and
407 then degenerate (Ehrenberg et al., 2017; Kelly et al., 2017; Theofilas et al., 2017). The frank
408 decline of noradrenergic cells is preceded by a period of dysfunctional neurotransmission in
409 LC's terminal regions like the mediotemporal lobe (Weinshenker, 2018). Thus, the negative
410 association between in vivo proxies for LC integrity and tau burden may signify a more
411 advanced Alzheimer's disease stage including noradrenergic neurodegeneration and wide-
412 spread tau pathology.

413

414 **MR-indexed locus coeruleus integrity is associated with cognitive deficits**

415 Finally, we found evidence for an association between MR-indexed LC integrity and
416 cognitive performance across several neuropsychological tests. Noradrenergic
417 neuromodulation has been implicated in a range of cognitive functions, prominently including
418 attention and memory (Berridge & Waterhouse, 2003; Bouret & Sara, 2005; Corbetta, Patel,
419 & Shulman, 2008; Mather, Clewett, Sakaki, & Harley, 2016; Sara, 2009). In particular,
420 mediated via β -adrenoceptors, norepinephrine release promotes long-term-potential in the
421 hippocampus—a key determinant of synaptic plasticity and memory (O'Dell, Connor,
422 Guglietta, & Nguyen, 2015). Recent optogenetic research moreover indicates a causal role of
423 LC activity in memory acquisition and consolidation, potentially supported by co-release of
424 dopamine (Duszkiewicz, McNamara, Takeuchi, & Genzel, 2019; Takeuchi et al., 2016;
425 Uematsu et al., 2017; Wagatsuma et al., 2018). Consistent with these observations in animals,
426 recent in vivo human research demonstrated an association between MR-indexed LC integrity
427 and memory performance in healthy aging (Dahl et al., 2019; Elman et al., 2020; Hämmerer
428 et al., 2018; Liu et al., 2020). Extending evidence from healthy populations, we here confirm
429 the behavioral relevance of MR-indexed LC integrity in tracking cognitive decline in a

430 clinical sample. Neuropsychological tests that proved sensitive to distinguish patients from
431 controls were reliably linked to LC integrity (González et al., 2002; Nasreddine et al., 2005;
432 O'Bryant et al., 2008; Teng et al., 1994). In line with reports indicating verbal learning tests as
433 effective early markers of Alzheimer's pathology (Albert et al., 2001; Belleville et al., 2017;
434 Moradi et al., 2017; Schoenberg et al., 2006), verbal learning and memory showed the closest
435 link to LC integrity (cf. Dahl et al., 2019, for analogous results in later life). Taken together,
436 our findings suggest that noradrenergic neurotransmission supports memory performance
437 whereas dysfunctions therein are associated with Alzheimer's related cognitive decline.

438

439 **Limitations and conclusions**

440 Some limitations should be noted. First, the contrast mechanisms underlying LC-
441 MRI constitute an active area of research (for a discussion, see Betts, Kirilina, et al., 2019)
442 and future studies may help determine what precise physiological processes are reflected in
443 MR-contrast differences. Second, as a cross-sectional observational study, it is not possible to
444 conclude a causative relationship between loss of LC integrity and cognitive symptoms and
445 deposition of abnormal tau in persons with ADAD. Finally, with a prevalence of about 5 cases
446 per 100,000 persons at risk, ADAD is a rare disease (Campion et al., 1999) accounting for less
447 than 1 % of all Alzheimer's cases (Bateman et al., 2011). All but one ADAD mutation carriers
448 in the current study had the same mutation in *PSENI* (A431E) which has specific features
449 (e.g., co-occurring spastic paraparesis and possibly atypical posterior-predominant tau
450 deposition) that may limit generalizability of the current findings. While providing insights
451 into the pathogenesis of Alzheimer's largely disentangled from factors associated with aging,
452 the presented findings need to be corroborated by longitudinal evidence in larger samples
453 (Lindenberger et al., 2011).

454 In conclusion, we applied a meta-analytical approach to advance the reliability and
455 validity of MR-based LC detection. Using non-invasive in vivo proxies, we revealed lower

456 LC integrity in symptomatic carriers of ADAD-causing mutations. Moreover, LC integrity
457 was strongly associated with cortical tau pathology and memory decline. In summary, this
458 provides support for a prominent role of the noradrenergic system in Alzheimer's disease
459 (Mather & Harley, 2016; Weinshenker, 2018).

460 **Material and methods**

461 **Aggregating across published locus coeruleus maps to derive a high confidence meta**
462 **mask**

463 Previous mapping studies used a variety of LC-sensitive MRI sequences (Turbo Spin
464 Echo [TSE; Dahl et al., 2019; Keren et al., 2009; Tona et al., 2017]; Magnetization Transfer
465 [MT; Liu et al., 2019; Ye et al., 2021]; Fast Low Angle Shot [FLASH; Betts et al., 2017]) at
466 different field strength (7 Tesla: Ye et al., 2021; 3 Tesla: all other studies) to visualize the
467 nucleus. Most investigations were conducted across younger and older adults or even within
468 lifespan samples (but see Tona et al., 2017 and Ye et al., 2021 for studies in younger and older
469 adults, respectively). After data collection, individual brainstem scans were transformed into a
470 group or standard space in which a manual (Betts et al., 2017; Liu et al., 2019; Tona et al.,
471 2017) or semi-automatic (Dahl et al., 2019; Keren et al., 2009; Ye et al., 2021) approach was
472 taken to segment the LC from surrounding tissue. While some earlier reports (Dahl et al.,
473 2019; Liu et al., 2019; Ye et al., 2021) include a comparison of a subset of the published
474 masks, to date there is no systematic evaluation of their agreement. More importantly, no
475 previous study attempted to resolve the apparent disagreement in LC dimensions and
476 localizations across publications.

477 In keeping with earlier analyses (Dahl et al., 2019; Liu et al., 2019; Ye et al., 2021),
478 the LC masks noted in Table 1 were used for cross-study comparisons. Before relating
479 different masks to one-another, all volumes were binarized and moved to a common space
480 (MNI-ICBM 152 linear space, 0.5 mm resolution), if necessary. In standard space, first an
481 unthresholded aggregate mask was generated using the following formula:

482
$$LC_{\text{aggregate}} = \frac{1}{n} \sum_{i=1}^n (v)$$

483 Whereby n denotes the number of masks included in the analyses ($n = 6$) and v
484 denotes the value for a given voxel (either zero [non-LC tissue] or one [LC]). That is, at every

485 voxel the individual binarized masks were averaged, resulting in an aggregate mask
486 ($LC_{aggregate}$; see Figure 1). The generated volume, $LC_{aggregate}$, showed a value range between 0
487 and 1 (complete agreement that a voxel does not/does belong to the LC, respectively) in steps
488 of $\frac{1}{n}$. Please note that we decided against weighing the contribution of the individual masks to
489 the $LC_{aggregate}$ by sample size as two masks (Dahl et al., 2019; Liu et al., 2019) account for
490 more than 80 % of the total number of participants (see Table 1). Hence, the aggregate would
491 be strongly biased in favor of a subset of masks that are themselves highly spatially congruent
492 (agreement 94%; Liu et al., 2019).

493 In a second step, the aggregate mask was pruned by removing low-agreement voxels
494 until a majority vote was achieved. That is, only areas with agreement values $> 50\%$ were
495 retained (i.e., more than $\frac{1}{2}n$ masks voted for a voxel to belong to the LC). Essentially, the
496 described mask generation process is comparable to label fusion with majority voting
497 (Rohlfing, Brandt, Menzel, & Maurer, 2004; Sabuncu, Yeo, Van Leemput, Fischl, & Golland,
498 2010; Wang et al., 2013) .

499 Finally, to obtain a biologically more plausible volume, the pruned aggregate mask
500 was smoothed with a 0.1 mm full width at half maximum (FWHM) kernel using SPM12
501 (Penny, Friston, Ashburner, Kiebel, & Nichols, 2007) in Matlab (The MathWorks Inc., Natick,
502 MA, USA). Voxels exceeding a threshold of 0.05 were considered part of the LC in the meta
503 mask ($LC_{metaMask}$; see Figure 1). The resulting mask had a rostrocaudal extent of 14 mm and a
504 volume of 74 mm³ (592 voxels), corresponding well with previous post-mortem findings
505 (Fernandes, Regala, Correia, & Gonçalves-Ferreira, 2012; Tona et al., 2017). We share the
506 generated meta mask with the scientific community via osf.io/sf2ky/

507

508

509 **Table 1:** Locus coeruleus masks included in comparisons

Publication	MRI acquisition	Sample	Locus coeruleus segmentaion	Mask source	Mask version	Note
Betts et al., 2017	3 T; FLASH	N = 82; YA; OA	Manual	https://doi.org/10.1016/j.neuroimage.2017.09.042	--	--
Dahl et al., 2019	3 T; TSE	N = 294; YA; OA	Semi-automatic	https://www.mpib-berlin.mpg.de/LC-Map	--	--
Keren et al., 2009	3 T; TSE	N = 44; YA-OA	Semi-automatic	http://www.eckertlab.org/LC	1 standard deviation	--
Liu et al., 2019	3 T; MT	N = 605; YA-OA	Manual	https://osf.io/r2bwk	--	--
Tona et al. 2017	3 T; TSE	N = 17; YA	Manual	http://www.nitrc.org/projects/prob_lc_3t	--	Mask averaged across scan sessions and segmentations
(Ye et al., 2021)	7 T; MT	N = 53; OA	Semi-automatic	https://www.nitrc.org/projects/lc_7t_prob	5% probability	Mask transformed from MNI-ICBM 152 non-linear 2009b to linear space ¹

510 Note: ¹The mask by Ye and colleagues was linearly and non-linearly co-registered to MNI-ICBM 152 linear space
 511 (0.5 mm resolution) using Advanced Normalization Tools (antsRegistration). MNI-ICBM 152 linear was chosen
 512 as target space as all but one masks share this space. For co-registration, the standard brains of the respective
 513 spaces were aligned and the transformations were applied to the mask file with a nearest neighbor interpolation.
 514 The transformations from MNI 2009b non-lin ⇔ MNI linear are shared via osf.io/sf2ky/; T, Tesla; FLASH,
 515 Fast Long Angle Shot; TSE, Turbo Spin Echo; MT, Magnetization Transfer; YA, Younger Adults, OA, Older
 516 Adults; YA-OA, lifespan sample including younger, middle-aged and older adults

517

518 **Evaluation of previously published locus coeruleus masks**

519 Once a high-agreement volume of interest ($LC_{metaMask}$) was established, published
 520 locus coeruleus masks were compared regarding their specificity and sensitivity. That is, we
 521 evaluated (1) how many voxels of a given mask fell within the $LC_{metaMask}$ relative to the total
 522 number of voxels in that mask and (2) how many voxels of the $LC_{metaMask}$ were included in
 523 each mask (relative to the total number of voxels in the $LC_{metaMask}$). The mean of the quality
 524 metrics (specificity, sensitivity) was taken as indicator for the accuracy of a mask.

525

526 **Application of locus coeruleus meta mask to an independent clinical sample**

527 **Study design and participants**

528 To determine whether the $LC_{metaMask}$ can detect clinically significant differences in LC
 529 integrity, eighteen participants with or known to be at-risk for mutations in genes associated

530 with ADAD (*PSENI* or *APP*) were investigated (34.7 ± 10.1 years [mean \pm standard
531 deviation]; 9♀; see Table 2; data collection was interrupted by the COVID-19 pandemic).
532 Participants' consent was obtained according to the Declaration of Helsinki. The study was
533 approved by the ethical committee of the University of Southern California. Data were
534 acquired as part of a study employing the Human Connectome Protocol (HCP) in genetic
535 subtypes of AD (NIH U01AG051218, PI: Ringman; see adrc.usc.edu/scientists-researchers/
536 for more details). Genotyping confirmed mutations in seven of the eighteen participants (the
537 A431E substitution in *PSENI*, $n = 6$; and the V717I substitution in *APP*, $n = 1$; Goate et al.,
538 1991; Murrell et al., 2006; Yescas et al., 2006), of which four were symptomatic (see Table 2).
539 Participants underwent 3 T MRI, flortaucipir PET, and cognitive testing. LC MR-intensity, a
540 non-invasive proxy for neuronal density (Keren et al., 2015), was semi-automatically
541 extracted from high-resolution brainstem scans (Dahl et al., 2019). LC ratios—that is, a ratio
542 of peak LC intensity standardized to a pontine reference (Betts, Kirilina, et al., 2019; Liu et
543 al., 2017)—were computed across the rostrocaudal extent of the nucleus. Standard uptake
544 value ratios (SUVR) were calculated from partial volume corrected flortaucipir PET data
545 using cerebellar gray matter as the reference based on the PETSURFER tool from FreeSurfer
546 (Greve et al., 2014). SUVR images were mapped to the cortical surface which was parcellated
547 into 36 regions of interest (Desikan et al., 2006). Univariate associations between LC ratios,
548 clinical variables, cognitive status, and tau burden were evaluated using non-parametric
549 Wilcoxon rank sum tests and bootstrapped Spearman's correlations. The multivariate pattern
550 between LC ratios, cortical tau burden and cognitive decline was evaluated using a partial
551 least squares correlation (see below; Krishnan, Williams, McIntosh, & Abdi, 2011; McIntosh
552 & Lobaugh, 2004). Two-tailed statistical tests were used with an alpha level of $p < 0.05$. The
553 applied statistical tests did not include covariates. Participants with missing data were
554 excluded from the respective analyses (see below). We did not conduct a formal power
555 calculation, given that there was no available prior evidence on the studied phenomena.

556 **Table 2:** Descriptive statistics for imaging subgroups

	ADAD-control	ADAD-presymptomatic	ADAD-symptomatic
n	11	3	4
Mutation	0/11	3/3	4/4
Mutation type		<i>PSEN1</i> (A431E; 3/3)	<i>PSEN1</i> (A431E; 3/4) <i>APP</i> (V717I; 1/4)
Diagnosis	0/11	0/3	4/4
CASI	95.1	92.7	74.9
(std, range)	(2.05; 92–97.7)	(3.785; 90–97)	(11.844; 62.8–86.8)
Age	33.1	29	43.5
(std, range)	(11.0; 19–58)	(6.1; 22–33)	(1.3; 42–45)
Gender	6 male 5 female	0 male 3 female	3 male 1 female

557 *Note:* ADAD, autosomal-dominant Alzheimer's disease; ADAD-control: control participants not carrying the
 558 mutation, but genetically related to mutation carriers; ADAD-presymptomatic: presymptomatic mutation carriers
 559 (Washington University Clinical Dementia Rating Scale [CDR] scores of 0); ADAD-symptomatic: symptomatic
 560 mutation carriers; std. standard deviation; CASI, Cognitive Abilities Screening Instrument (Teng et al., 1994);
 561 *PSEN1*: Presenilin-1 protein (gene); *APP*: Amyloid- β Precursor Protein (gene)
 562

563

564 **Assessment of imaging data**

565 Structural MRI data were collected employing a 3 T Siemens Prisma scanner with a
 566 32-channel head coil following a Human Connectome Project imaging approach (HCP; cf.
 567 humanconnectome.org/). Only those sequences used in the current analyses are described
 568 below.

569 A three-dimensional (3D) T1-weighted magnetization prepared gradient-echo
 570 (MPRAGE) sequence with a duration of 6:38 min and the following parameters was applied:
 571 repetition time (TR) = 2400 ms; echo time (TE) = 2.22 ms; inversion time (TI) = 1000 ms;
 572 flip angle = 8°; bandwidth = 220 Hz/Px; dimensions = 208 × 300 × 320; isometric voxel size
 573 = 0.8 mm³. Based on this whole-brain (MPRAGE) sequence, a high-resolution, two-
 574 dimensional (2D) T1-weighted TSE sequence was aligned perpendicularly to the plane of the
 575 brainstem. Acquisition of the TSE sequence took 1:53 min, and the following parameters
 576 were used: TR = 750 ms; TE = 10 ms; flip angle = 120°; bandwidth = 285 Hz/Px; dimensions
 577 = 512 × 512 × 11; anisometric voxel size = 0.43 × 0.43 × 3.5 mm³ (mimicking the elongated
 578 shape of the locus coeruleus). Each TSE scan consisted of eleven axial slices.

579 PET data were collected using a 3 T Siemens Prisma scanner within the period of 90–
580 120 min after the injection of the compound 18F-AV-1451 (total dose: 344 MBq). Low dose
581 computerized tomography (CT) scans were acquired prior to the PET scans for attenuation
582 correction. The dynamic PET scans included six frames of five-minute duration, with the
583 dimensions of $168 \times 168 \times 56$ and a voxel size of $1.5 \times 1.5 \times 4 \text{ mm}^3$. The six dynamic scans
584 were rigidly aligned to the first one and averaged to create a static image for SUVR-based
585 analysis.

586

587 **Semi-automatic locus coeruleus intensity assessment using meta mask**

588 Leveraging the generated $LC_{metaMask}$ (see above), locus coeruleus intensity was semi-
589 automatically extracted using a previously validated pipeline (Dahl et al., 2019; also see Ye et
590 al., 2021 for a comparable approach). In short, individual whole brain and brainstem scans
591 were iteratively aligned across participants using a template-based procedure implemented in
592 Advanced Normalization Tools (version 2.1; ANTs; Avants et al., 2011; Avants, Tustison, &
593 Song, 2009), and subsequently transformed to standard space (MNI-ICBM 152 linear, 0.5
594 mm; see Dahl et al., 2019 for a step-by-step description of the standardization). In standard
595 space, individual brainstem scans were masked using the high-confidence $LC_{metaMask}$ to
596 remove non-LC tissue (using SPM12 in Matlab). To allow inter-subject comparisons of LC
597 data, a normalization of the arbitrarily scaled MR-intensity values is required (Betts, Kirilina,
598 et al., 2019). Thus, brainstem scans were additionally masked using a reference volume of
599 interest positioned in the central pontine white matter, as previously suggested (Ye et al.,
600 2021; dimensions: $4 \times 4 \text{ mm}$ in plane, following the $LC_{metaMask}$ with a constant distance of 8.5
601 mm [y-dimension] along the rostrocaudal axis; see Figure 3). Within the masked brainstem
602 scans, we then fully automatically searched for voxels of brightest intensity in the LC and
603 reference regions. Next, individual, spatially-resolved LC intensity ratios were computed for
604 each slice using the following formula (Dahl et al., 2019; Liu et al., 2017):

605
$$LC_{Ratio} = \frac{\max(LC) - \max(Ref)}{\max(Ref)}$$

606 Where $\max(LC)$ denotes the peak intensity for a given slice in the LC volume of interest and
607 $\max(Ref)$ indicates the peak intensity in the reference region. After extraction, ratios of the left
608 and right hemisphere were averaged for further analyses to obtain more stable intensity
609 estimates. Finally, the peak ratio across the rostrocaudal LC extent was calculated as proxy for
610 overall locus coeruleus integrity.

611

612 **Assessment of cortical tau burden**

613 To evaluate the association of MR-indexed LC integrity to hallmarks of AD, we
614 calculated cortical tau burden from flortaucipir PET data.

615 First, each participant's whole brain MR data (MPRAGE) was preprocessed using a
616 HCP pipeline (version 3.27; Makropoulos et al., 2018). Next, the cortical surface was
617 reconstructed and parcellated into thirty-six anatomical regions of interest using Freesurfer
618 6.0 (Dale, Fischl, & Sereno, 1999; Desikan et al., 2006). Flortaucipir PET images were then
619 co-registered within participants to whole brain (MPRAGE) native space. The Muller-Gartner
620 (MG) method was used for partial volume correction of the PET data, as implemented in
621 PETSURFER (Greve et al., 2016). Standard uptake value ratios (SUVR) were calculated using
622 cerebellar gray matter as reference region. Finally, partial-volume corrected SUVR images
623 were mapped to the cortical surface and parcellated into thirty-six regions of interest (Desikan
624 et al., 2006). For further analyses, each region's SUVR data were averaged across
625 hemispheres to obtain more stable estimates of cortical tau burden. Tau PET data were not
626 available for two subjects.

627

628 **Association of locus coeruleus intensity and cortical tau burden**

629 We employed a multivariate statistical approach to assess the relation between MR-
630 indexed locus coeruleus integrity and tau pathology across the cortex. Specifically, using a
631 Partial Least Squares Correlation (PLSC; Krishnan et al., 2011; McIntosh & Lobaugh, 2004)
632 we estimated a latent tau pathology profile that is maximally related to LC integrity (cf.
633 Keresztes et al., 2017; Muehlroth et al., 2020).

634 First, a between-person Pearson's correlation matrix (R) was computed between the
635 overall LC ratios (i.e., a vector Y_{LC} with $n_{\text{Participants}} \times 1$ [overall intensity ratios]) and the tau
636 SUVR data (i.e., a matrix X_{Tau} with $n_{\text{Participants}} \times 36$ [regions of interest]). This correlation
637 matrix ($R_{LC, \text{Tau}} = Y_{LC}^T X_{\text{Tau}}$) was then decomposed into three matrices using a singular value
638 decomposition (SVD; $\text{SVD}(R_{LC, \text{Tau}}) = USV^T$). Whereby U refers to a left singular vector of LC
639 weights, V^T denotes a right singular matrix of regional tau weights, and S is a diagonal matrix
640 of singular values. Based on this matrix decomposition, a single latent variable was extracted.
641 The latent variable optimally expresses (in a least squares sense) the pattern of interindividual
642 differences in regional tau burden that shares the largest amount of variance with
643 interindividual differences in overall LC intensity ratios. The statistical strength of the
644 extracted pattern (i.e., the latent variable) was evaluated using a permutation test (by
645 randomly re-ordering the observations in X_{Tau} while leaving Y_{LC} unchanged and re-calculating
646 the SVD; $n_{\text{Permutations}} = 10,000$). Subsequently, the reliability of the contribution (i.e., weights
647 [V^T]) of individual cortical regions, that is, the columns in X_{Tau} , to this latent variable was
648 determined using a bootstrapping procedure ($n_{\text{BooTraps}} = 10,000$). A ratio of the region-specific
649 weights (V^T) and their corresponding bootstrapped standard errors provided bootstrap ratios
650 (BSR) that can be interpreted akin to Z-scores. Finally, multiplying participants' regional
651 pattern of tau pathology (X_{Tau}) with each regions' contribution to the latent variable (i.e., its
652 weight, V^T) yielded a summary measure, reflecting participants' LC-related tau pathology.

653

654 **Cognitive assessments**

655 Participants completed a series of standardized neuropsychological tests to assess
656 memory and attention. The cognitive assessment included screening instruments (the
657 Montreal Cognitive Assessment [MoCA, Nasreddine et al., 2005]; the Cognitive Abilities
658 Screening Instrument [CASI; Teng et al., 1994], and the Washington University Clinical
659 Dementia Rating Scale [CDR; measure: sum of boxes; cf. O'Bryant et al., 2008]). In addition,
660 attention (Digit-Symbol-Substitution Test [DSST; Wechsler, 1981]; Digit Span [measure:
661 backward report; Wechsler, 1997], Trail Making Test [measure: part B; Tombaugh, 2004]) and
662 memory performance were assessed (the Spanish English Verbal Learning Test [SEVLT;
663 measures: average performance over learning trials and delayed recall; González, Mungas, &
664 Haan, 2002], a learning and memory test akin to the Rey Auditory Verbal Learning Test
665 [RAVLT] in which Spanish and English versions were simultaneously developed; Benson
666 Complex Figure Test [measure: delayed recall; cf. Possin, Laluz, Alcantar, Miller, & Kramer,
667 2011]; and the Craft Story Test [delayed recall; Craft et al., 1996]). When available, for
668 further analyses individual test scores were transformed to Z-scores using published
669 normative data. Trail making data were not available for one subject.

670 A partial least squares correlation (PLSC; Krishnan et al., 2011; McIntosh & Lobaugh,
671 2004) was applied to capture the multivariate association between MR-indexed LC integrity
672 and cognitive performance, using the same methods as described above.

673

674 **Neuropathological assessment**

675 To characterize the pathology underlying the LC signal on MRI in ADAD, we
676 examined the LC in an independent sample of four persons dying with the A431E mutation in
677 *PSEN1* in comparison to five age-matched neurologically normal controls. In short, paraffin-
678 embedded sections of the pons were cut and stained with hematoxylin and eosin (H&E), glial
679 fibrillary acid protein (GFAP), AT8 antibodies for neurofibrillary pathology, 4G8 antibodies

680 for amyloid- β , and anti-alpha synuclein antibodies for Lewy Body pathology. Qualitative
681 comparisons were made between patients and controls.

682

683 **Histopathology methods**

684 After 1-month fixation, tissue areas were dissected and paraffin-embedded and serially
685 sectioned into 5 μ m-thick sections using a microtome (Microm International Waldorf,
686 Germany). Brain sections were counterstained with H&E and reagents were purchased from
687 Sigma-Aldrich (St. Louis, MO, USA). Sections adjacent to H&E were immunostained using
688 the Leica Bond RXm™ automated staining processor (Leica Biosystems, Buffalo Grove, IL,
689 USA). Tissue sections were stained using the Bond Polymer Refine AFP (Red) Detection
690 System for all Abs except GFAP Ab and NeuN Ab which used Bond Polymer Refine DAB
691 Detection System (Leica Biosystems). Antigen retrieval was performed with Epitope
692 Retrieval Solution 1 (ER1, pH 6) for 20 min except for GFAP Ab which was for 10 min.
693 Sections were then incubated with amyloid-beta (4G8, BioLegend, SIG #800701, 1:4000) for
694 30 min, TAR DNA binding protein (TDP-43, Sigma, T11705; 1:1250) for 15 min, phosphor-
695 tau (AT8, MN1020, Thermo Scientific, USA; 1:1000 for 15 min; GFAP Rb pAb, Chemicon,
696 Temecula AB5804, CA, USA; 1:2500) for 15 min; (NeuN, AbCAM, ab104224, USA; 1:800)
697 for 30m. a-Synuclein Rb pAb, Chemicon, AB5038, 1:2000 for 15 min.

698 Staining with 4-repeat isoform tau (RD4, Cosmo Bio Co. LTD. Inspiration of Life
699 Science, Cat# TIP-4RT-P01; 1:3000) and 3-repeat isoform tau (RD3, 05-803, Millipore,
700 USA; 1:5000) required manual pretreatment outside autostainer. Sections heated in a pressure
701 cooker at 125° in citrate buffer (CC2, pH 6) for 90 min and treated with 88% Formic Acid for
702 10 min. Sections were then loaded in autostainer with Bond Polymer Refine Red Detection
703 System for 15 min. Images were obtained with a Nikon Eclipse E400 brightfield microscope
704 (Nikon Instruments Inc, Melville, NY, USA). All stains were performed at Children's
705 Hospital of Los Angeles.

706

707 **Data availability**

708 The here described LC meta mask as well as pontine reference mask is available for
709 download on an Open Science Framework repository (osf.io/sf2ky/). All sources for
710 previously published masks are listed in Table 1. For access to raw imaging and clinical data,
711 please refer to the HCP (<https://nda.nih.gov/ccf/>).

712

713 **Acknowledgements**

714 The authors thank all study participants for their contribution.

715

716 **Competing interests**

717 The authors declare no competing financial interests.

718

719 **Funding**

720 MJD is recipient of a stipend from the GA. Lienert-Foundation and was supported by a stipend from the Davis
721 School of Gerontology, University of Southern California. MM's work was supported by National Institutes of
722 Health (NIH) grant R01AG025340, an Alexander von Humboldt fellowship, and a Max Planck Sabbatical
723 Award. MW-B received support from the German Research Foundation (DFG, WE 4269/5-1) and the Jacobs
724 Foundation (Early Career Research Fellowship 2017–2019). BLK was supported by a NIH grant F32AG057162.
725 YS was supported by NIH grants RF1AG064584 and RF1AG056573. SG, KH, and CCM were supported by
726 P30AG066530, JMR was supported by NIH grants U01AG051218, R01AG062007, and P30AG066530. The
727 funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
728 manuscript.

729

730 **References**

- 731 Albert, M. S., Moss, M. B., Tanzi, R., & Jones, K. (2001). Preclinical prediction of AD using
732 neuropsychological tests. *Journal of the International Neuropsychological Society*, 7(5),
733 631–639. <https://doi.org/10.1017/S1355617701755105>
- 734 Alzheimer's Disease International. (2019). World Alzheimer Report 2019: Attitudes to
735 Dementia. *Alzheimer's Disease International: London*.
- 736 Arendt, T., Brückner, M. K., Morawski, M., Jäger, C., & Gertz, H. J. (2015). Early neurone
737 loss in Alzheimer's disease: cortical or subcortical? *Acta Neuropathologica*
738 *Communications*, 3, 10. <https://doi.org/10.1186/s40478-015-0187-1>
- 739 Astafiev, S. V., Snyder, A. Z., Shulman, G. L., & Corbetta, M. (2010). Comment on
740 “Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during
741 functional MRI” and “Homeostatic sleep pressure and responses to sustained attention in
742 the suprachiasmatic area.” *Science*, 328(5976), 309.
743 <https://doi.org/10.1126/science.1177200>
- 744 Avants, B. B., Tustison, N. J., Song, G., Cook, P. A., Klein, A., & Gee, J. C. (2011). A
745 reproducible evaluation of ANTs similarity metric performance in brain image
746 registration. *NeuroImage*, 54(3), 2033–2044.
747 <https://doi.org/10.1016/j.neuroimage.2010.09.025>
- 748 Avants, B. B., Tustison, N., & Song, G. (2009). Advanced Normalization Tools: V1.0. *Insight*
749 *Journal*, 2. <https://doi.org/http://hdl.handle.net/10380/3113>
- 750 Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., ...
751 Xiong, C. (2011, January 6). Autosomal-dominant Alzheimer's disease: A review and
752 proposal for the prevention of Alzheimer's disease. *Alzheimer's Research and Therapy*.
753 BioMed Central. <https://doi.org/10.1186/alzrt59>
- 754 Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., ... Morris,
755 J. C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's

- 756 disease. *New England Journal of Medicine*, 367(9), 795–804.
- 757 <https://doi.org/10.1056/NEJMoa1202753>
- 758 Belleville, S., Fouquet, C., Hudon, C., Zomahoun, H. T. V., & Croteau, J. (2017).
- 759 Neuropsychological measures that predict progression from mild cognitive impairment
- 760 to Alzheimer's type dementia in older adults: A systematic review and meta-analysis.
- 761 *Neuropsychology Review*, 27(4), 328–353. <https://doi.org/10.1007/s11065-017-9361-5>
- 762 Berridge, C. W., & Waterhouse, B. D. (2003). The locus coeruleus-noradrenergic system:
- 763 Modulation of behavioral state and state-dependent cognitive processes. *Brain Research*
- 764 *Reviews*, 42(1), 33–84. [https://doi.org/10.1016/S0165-0173\(03\)00143-7](https://doi.org/10.1016/S0165-0173(03)00143-7)
- 765 Bertram, L., Lill, C. M., & Tanzi, R. E. (2010, October 21). The genetics of alzheimer disease:
- 766 Back to the future. *Neuron*. *Neuron*. <https://doi.org/10.1016/j.neuron.2010.10.013>
- 767 Betts, M. J., Cardenas-Blanco, A., Kanowski, M., Jessen, F., & Düzel, E. (2017). In vivo MRI
- 768 assessment of the human locus coeruleus along its rostrocaudal extent in young and older
- 769 adults. *NeuroImage*, 163, 150–159. <https://doi.org/10.1016/j.neuroimage.2017.09.042>
- 770 Betts, M. J., Cardenas-Blanco, A., Kanowski, M., Spottke, A., Teipel, S. J., Kilimann, I., ...
- 771 Düzel, E. (2019). Locus coeruleus MRI contrast is reduced in Alzheimer's disease
- 772 dementia and correlates with CSF A β levels. *Alzheimer's & Dementia: Diagnosis,*
- 773 *Assessment & Disease Monitoring*, 11, 281–285.
- 774 <https://doi.org/10.1016/j.dadm.2019.02.001>
- 775 Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M.
- 776 F., ... Hämmerer, D. (2019). Locus coeruleus imaging as a biomarker for noradrenergic
- 777 dysfunction in neurodegenerative diseases. *Brain*, 142(9), 2558–2571.
- 778 <https://doi.org/10.1093/brain/awz193>
- 779 Bouret, S., & Sara, S. J. (2005). Network reset: A simplified overarching theory of locus
- 780 coeruleus noradrenaline function. *Trends in Neurosciences*, 28(11), 574–582.
- 781 <https://doi.org/10.1016/j.tins.2005.09.002>

- 782 Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011). Stages of the pathologic
783 process in Alzheimer disease: Age categories from 1 to 100 years. *Journal of*
784 *Neuropathology and Experimental Neurology*, 70(11), 960–969.
785 <https://doi.org/10.1097/NEN.0b013e318232a379>
- 786 Champion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., ... Frebourg,
787 T. (1999). Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic
788 heterogeneity, and mutation spectrum. *American Journal of Human Genetics*, 65(3),
789 664–670. <https://doi.org/10.1086/302553>
- 790 Canter, R. G., Penney, J., & Tsai, L. H. (2016, November 9). The road to restoring neural
791 circuits for the treatment of Alzheimer's disease. *Nature*. Nature Publishing Group.
792 <https://doi.org/10.1038/nature20412>
- 793 Cassidy, C. M., Zucca, F. A., Girgis, R. R., Baker, S. C., Weinstein, J. J., Sharp, M. E., ...
794 Horga, G. (2019). Neuromelanin-sensitive MRI as a noninvasive proxy measure of
795 dopamine function in the human brain. *Proceedings of the National Academy of Sciences*
796 *of the United States of America*, 116(11), 5108–5117.
797 <https://doi.org/10.1073/pnas.1807983116>
- 798 Chalermplanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C., Lah, J. J., Levey, A. I.,
799 & Weinshenker, D. (2018). Locus coeruleus ablation exacerbates cognitive deficits,
800 neuropathology, and lethality in P301S tau transgenic mice. *The Journal of*
801 *Neuroscience : The Official Journal of the Society for Neuroscience*, 38(1), 74–92.
802 <https://doi.org/10.1523/JNEUROSCI.1483-17.2017>
- 803 Chalermplanupap, T., Weinshenker, D., & Rorabaugh, J. M. (2017). Down but not out: The
804 consequences of pretangle tau in the locus coeruleus. *Neural Plasticity*, 2017, 7829507.
805 <https://doi.org/10.1155/2017/7829507>
- 806 Corbetta, M., Patel, G., & Shulman, G. L. (2008). The reorienting system of the human brain:
807 From environment to theory of mind. *Neuron*, 58(3), 306–324.

- 808 <https://doi.org/10.1016/j.neuron.2008.04.017>
- 809 Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., ... Alderson, A.
810 (1996). Memory improvement following induced hyperinsulinemia in Alzheimer's
811 disease. *Neurobiology of Aging*, *17*(1), 123–130. <https://doi.org/10.1016/0197->
812 [4580\(95\)02002-0](https://doi.org/10.1016/0197-4580(95)02002-0)
- 813 Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I.,
814 ... Nelson, P. T. (2014). Primary age-related tauopathy (PART): a common pathology
815 associated with human aging. *Acta Neuropathologica*, *128*(6), 755–766.
816 <https://doi.org/10.1007/s00401-014-1349-0>
- 817 Dahl, M. J., Mather, M., Düzel, S., Bodammer, N. C., Lindenberger, U., Kühn, S., & Werkle-
818 Bergner, M. (2019). Rostral locus coeruleus integrity is associated with better memory
819 performance in older adults. *Nature Human Behaviour*, *3*(11), 1203–1214.
820 <https://doi.org/10.1038/s41562-019-0715-2>
- 821 Dahl, M. J., Mather, M., Sander, M. C., & Werkle-Bergner, M. (2020). Noradrenergic
822 responsiveness supports selective attention across the adult lifespan. *Journal of*
823 *Neuroscience*, *40*(22), 4372–4390. <https://doi.org/10.1523/JNEUROSCI.0398-19.2020>
- 824 Dale, A. M., Fischl, B., & Sereno, M. I. (1999). Cortical surface-based analysis: I.
825 Segmentation and surface reconstruction. *NeuroImage*, *9*(2), 179–194.
826 <https://doi.org/10.1006/nimg.1998.0395>
- 827 Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., ...
828 Killiany, R. J. (2006). An automated labeling system for subdividing the human cerebral
829 cortex on MRI scans into gyral based regions of interest. *NeuroImage*, *31*(3), 968–980.
830 <https://doi.org/10.1016/j.neuroimage.2006.01.021>
- 831 Dordevic, M., Müller-Fotti, A., Müller, P., Schmicker, M., Kaufmann, J., & Müller, N. G.
832 (2017). Optimal Cut-Off Value for Locus Coeruleus-to-Pons Intensity Ratio as Clinical
833 Biomarker for Alzheimer's Disease: A Pilot Study. *Journal of Alzheimer's Disease*

- 834 *Reports*, 1(1), 159–167. <https://doi.org/10.3233/adr-170021>
- 835 Duzskiewicz, A. J., McNamara, C. G., Takeuchi, T., & Genzel, L. (2019). Novelty and
836 Dopaminergic Modulation of Memory Persistence: A Tale of Two Systems. *Trends in*
837 *Neurosciences*, 42(2), 102–114. <https://doi.org/10.1016/J.TINS.2018.10.002>
- 838 Ehrenberg, A. J., Nguy, A. K., Theofilas, P., Dunlop, S., Suemoto, C. K., Di Lorenzo Alho, A.
839 T., ... Grinberg, L. T. (2017). Quantifying the accretion of hyperphosphorylated tau in
840 the locus coeruleus and dorsal raphe nucleus: The pathological building blocks of early
841 Alzheimer's disease. *Neuropathology and Applied Neurobiology*, 43(5), 393–408.
842 <https://doi.org/10.1111/nan.12387>
- 843 Elman, J. A., Puckett, O. K., Beck, A., Panizzon, M. S., Sanderson-Cimino, M. E., Gustavson,
844 D. E., ... Kremen, W. S. (2020). MRI-assessed locus coeruleus integrity is heritable and
845 associated with cognition, Alzheimer's risk, and sleep-wake disturbance. *Alzheimer's &*
846 *Dementia*, 16(S5). <https://doi.org/10.1002/alz.044862>
- 847 Fernandes, P., Regala, J., Correia, F., & Gonçalves-Ferreira, A. J. (2012). The human locus
848 coeruleus 3-D stereotactic anatomy. *Surgical and Radiologic Anatomy*, 34(10), 879–885.
849 <https://doi.org/10.1007/s00276-012-0979-y>
- 850 Ghosh, A., Torraville, S. E., Mukherjee, B., Walling, S. G., Martin, G. M., Harley, C. W., &
851 Yuan, Q. (2019). An experimental model of Braak's pretangle proposal for the origin of
852 Alzheimer's disease: The role of locus coeruleus in early symptom development.
853 *Alzheimer's Research and Therapy*, 11(1), 59. [https://doi.org/10.1186/s13195-019-0511-](https://doi.org/10.1186/s13195-019-0511-2)
854 2
- 855 Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., ... Hardy,
856 J. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with
857 familial Alzheimer's disease. *Nature*, 349(6311), 704–706.
858 <https://doi.org/10.1038/349704a0>
- 859 González, H. M., Mungas, D., & Haan, M. N. (2002). A verbal learning and memory test for

- 860 English- and Spanish-speaking older Mexican-American adults. *Clinical*
861 *Neuropsychologist*, 16(4), 439–451. <https://doi.org/10.1076/clin.16.4.439.13908>
- 862 Greve, D. N., Salat, D. H., Bowen, S. L., Izquierdo-Garcia, D., Schultz, A. P., Catana, C., ...
863 Johnson, K. A. (2016). Different partial volume correction methods lead to different
864 conclusions: An 18F-FDG-PET study of aging. *NeuroImage*, 132, 334–343.
865 <https://doi.org/10.1016/j.neuroimage.2016.02.042>
- 866 Greve, D. N., Svarer, C., Fisher, P. M., Feng, L., Hansen, A. E., Baare, W., ... Knudsen, G. M.
867 (2014). Cortical surface-based analysis reduces bias and variance in kinetic modeling of
868 brain PET data. *NeuroImage*, 92, 225–236.
869 <https://doi.org/10.1016/j.neuroimage.2013.12.021>
- 870 Grinberg, L. T., & Heinsen, H. (2017). Light at the beginning of the tunnel? Investigating
871 early mechanistic changes in Alzheimer's disease. *Brain*, 140(11), 2770–2773.
872 <https://doi.org/10.1093/brain/awx261>
- 873 Hämmerer, D., Callaghan, M. F., Hopkins, A., Kosciessa, J., Betts, M., Cardenas-Blanco, A.,
874 ... Düzel, E. (2018). Locus coeruleus integrity in old age is selectively related to
875 memories linked with salient negative events. *Proceedings of the National Academy of*
876 *Sciences of the United States of America*, 115, 2228–2233.
877 <https://doi.org/10.1073/pnas.1712268115>
- 878 Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A.,
879 ... Johnson, K. (2019). Association of amyloid and tau with cognition in preclinical
880 Alzheimer disease. *JAMA Neurology*, Advance online publication.
881 <https://doi.org/10.1001/jamaneurol.2019.1424>
- 882 Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L.,
883 Terwel, D., ... Kummer, M. P. (2010). Locus ceruleus controls Alzheimer's disease
884 pathology by modulating microglial functions through norepinephrine. *Proceedings of*
885 *the National Academy of Sciences of the United States of America*, 107(13), 6058–6063.

- 886 <https://doi.org/10.1073/pnas.0909586107>
- 887 Jacobs, H. I. L., Becker, A., Sperling, R. A., Guzman-Velez, E., Baena, A., Uquillas, F.
- 888 d'Oleire, ... Quiroz, Y. T. (2019). P2-425: Locus coeruleus intensity is associated with
- 889 early amyloid and tau pathology in preclinical autosomal dominant Alzheimer's disease.
- 890 *Alzheimer's & Dementia*, 15, P774–P775. <https://doi.org/10.1016/j.jalz.2019.06.2832>
- 891 Jacobs, H. I. L., Riphagen, J. M., Ramakers, I. H. G. B., & Verhey, F. R. J. (2019).
- 892 Alzheimer's disease pathology: Pathways between central norepinephrine activity,
- 893 memory, and neuropsychiatric symptoms. *Molecular Psychiatry*, Advance online
- 894 publication. <https://doi.org/10.1038/s41380-019-0437-x>
- 895 Jagust, W. (2018). Imaging the evolution and pathophysiology of Alzheimer disease. *Nature*
- 896 *Reviews Neuroscience*, 19, 687–700. <https://doi.org/10.1038/s41583-018-0067-3>
- 897 Janssen, J. C., Hall, M., Fox, N. C., Harvey, R. J., Beck, J., Dickinson, A., ... Rossor, M. N.
- 898 (2000). Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation. A
- 899 clinicopathological study. *Brain*, 123(5), 894–907.
- 900 <https://doi.org/10.1093/brain/123.5.894>
- 901 Jessen, F., Spottke, A., Boecker, H., Brosseron, F., Buerger, K., Catak, C., ... Düzel, E.
- 902 (2018). Design and first baseline data of the DZNE multicenter observational study on
- 903 predementia Alzheimer's disease (DELCODE). *Alzheimer's Research & Therapy*, 10, 15.
- 904 <https://doi.org/10.1186/s13195-017-0314-2>
- 905 Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017).
- 906 Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's
- 907 disease. *Acta Neuropathologica Communications*, 5(1), 8.
- 908 <https://doi.org/10.1186/s40478-017-0411-2>
- 909 Keren, N. I., Lozar, C. T., Harris, K. C., Morgan, P. S., & Eckert, M. A. (2009). In vivo
- 910 mapping of the human locus coeruleus. *NeuroImage*, 47(4), 1261–1267.
- 911 <https://doi.org/10.1016/j.neuroimage.2009.06.012>

- 912 Keren, N. I., Taheri, S., Vazey, E. M., Morgan, P. S., Granholm, A. C. E., Aston-Jones, G., &
913 Eckert, M. A. (2015). Histologic validation of locus coeruleus MRI contrast in post-
914 mortem tissue. *NeuroImage*, *113*, 235–245.
915 <https://doi.org/10.1016/j.neuroimage.2015.03.020>
- 916 Keresztes, A., Bender, A. R., Bodammer, N. C., Lindenberger, U., Shing, Y. L., & Werkle-
917 Bergner, M. (2017). Hippocampal maturity promotes memory distinctiveness in
918 childhood and adolescence. *Proceedings of the National Academy of Sciences of the*
919 *United States of America*, *114*(34), 9212–9217. <https://doi.org/10.1073/pnas.1710654114>
- 920 Klein, A., Andersson, J., Ardekani, B. A., Ashburner, J., Avants, B., Chiang, M.-C., ... Parsey,
921 R. V. (2009). Evaluation of 14 nonlinear deformation algorithms applied to human brain
922 MRI registration. *NeuroImage*, *46*(3), 786–802.
923 <https://doi.org/10.1016/J.NEUROIMAGE.2008.12.037>
- 924 Krishnan, A., Williams, L. J., McIntosh, A. R., & Abdi, H. (2011). Partial Least Squares (PLS)
925 methods for neuroimaging: A tutorial and review. *NeuroImage*, *56*(2), 455–475.
926 <https://doi.org/10.1016/j.neuroimage.2010.07.034>
- 927 La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., ... Rabinovici, G.
928 D. (2020). Prospective longitudinal atrophy in Alzheimer's disease correlates with the
929 intensity and topography of baseline tau-PET. *Science Translational Medicine*, *12*(524),
930 eaau5732. <https://doi.org/10.1126/scitranslmed.aau5732>
- 931 Lee, T.-H., Greening, S. G., Ueno, T., Clewett, D., Ponzio, A., Sakaki, M., & Mather, M.
932 (2018). Arousal increases neural gain via the locus coeruleus–noradrenaline system in
933 younger adults but not in older adults. *Nature Human Behaviour*, *2*(5), 356–366.
934 <https://doi.org/10.1038/s41562-018-0344-1>
- 935 Lindenberger, U., von Oertzen, T., Ghisletta, P., & Hertzog, C. (2011). Cross-sectional age
936 variance extraction: What's change got to do with it? *Psychology and Aging*, *26*(1), 34–
937 47. <https://doi.org/10.1037/a0020525>

- 938 Liu, K. Y., Acosta-Cabronero, J., Cardenas-Blanco, A., Loane, C., Berry, A. J., Betts, M. J., ...
939 Hämmerer, D. (2019). In vivo visualization of age-related differences in the locus
940 coeruleus. *Neurobiology of Aging*, *74*, 101–111.
941 <https://doi.org/10.1016/j.neurobiolaging.2018.10.014>
- 942 Liu, K. Y., Kievit, R. A., Tsvetanov, K. A., Betts, M. J., Düzel, E., Rowe, J. B., ... Hämmerer,
943 D. (2020). Noradrenergic-dependent functions are associated with age-related locus
944 coeruleus signal intensity differences. *Nature Communications*, *11*(1), 1712.
945 <https://doi.org/10.1038/s41467-020-15410-w>
- 946 Liu, K. Y., Marijatta, F., Hämmerer, D., Acosta-Cabronero, J., Düzel, E., & Howard, R. J.
947 (2017). Magnetic resonance imaging of the human locus coeruleus: A systematic review.
948 *Neuroscience and Biobehavioral Reviews*, *83*, 325–355.
949 <https://doi.org/10.1016/j.neubiorev.2017.10.023>
- 950 Lyness, S. A., Zarow, C., & Chui, H. C. (2003, January 1). Neuron loss in key cholinergic and
951 aminergic nuclei in Alzheimer disease: A meta-analysis. *Neurobiology of Aging*. Elsevier.
952 [https://doi.org/10.1016/S0197-4580\(02\)00057-X](https://doi.org/10.1016/S0197-4580(02)00057-X)
- 953 Mäki-Marttunen, V., & Espeseth, T. (2020). Uncovering the locus coeruleus: comparison of
954 localization methods for functional analysis. *NeuroImage*, 117409.
955 <https://doi.org/10.1016/j.neuroimage.2020.117409>
- 956 Makropoulos, A., Robinson, E. C., Schuh, A., Wright, R., Fitzgibbon, S., Bozek, J., ...
957 Rueckert, D. (2018). The developing human connectome project: A minimal processing
958 pipeline for neonatal cortical surface reconstruction. *NeuroImage*, *173*, 88–112.
959 <https://doi.org/10.1016/j.neuroimage.2018.01.054>
- 960 Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004). Noradrenergic mechanisms in
961 neurodegenerative diseases: A theory. *Brain Research Reviews*, *45*(1), 38–78.
962 <https://doi.org/10.1016/j.brainresrev.2004.02.002>
- 963 Mather, M., Clewett, D., Sakaki, M., & Harley, C. W. (2016). Norepinephrine ignites local

- 964 hotspots of neuronal excitation: How arousal amplifies selectivity in perception and
965 memory. *Behavioral and Brain Sciences*, 39, e200.
966 <https://doi.org/10.1017/S0140525X15000667>
- 967 Mather, M., & Harley, C. W. (2016). The locus coeruleus: Essential for maintaining cognitive
968 function and the aging brain. *Trends in Cognitive Sciences*, 20(3), 214–226.
969 <https://doi.org/10.1016/j.tics.2016.01.001>
- 970 McIntosh, A. R., & Lobaugh, N. J. (2004). Partial least squares analysis of neuroimaging data:
971 Applications and advances. In *NeuroImage* (Vol. 23). Neuroimage.
972 <https://doi.org/10.1016/j.neuroimage.2004.07.020>
- 973 Miyoshi, F., Ogawa, T., Kitao, S. I., Kitayama, M., Shinohara, Y., Takasugi, M., ... Kaminou,
974 T. (2013). Evaluation of Parkinson disease and Alzheimer disease with the use of
975 neuromelanin MR imaging and¹²³I-metaiodobenzylguanidine scintigraphy. *American*
976 *Journal of Neuroradiology*, 34(11), 2113–2118. <https://doi.org/10.3174/ajnr.A3567>
- 977 Moradi, E., Hallikainen, I., Hänninen, T., & Tohka, J. (2017). Rey's Auditory Verbal Learning
978 Test scores can be predicted from whole brain MRI in Alzheimer's disease. *NeuroImage:*
979 *Clinical*, 13, 415–427. <https://doi.org/10.1016/j.nicl.2016.12.011>
- 980 Muehlroth, B. E., Sander, M. C., Fandakova, Y., Grandy, T. H., Rasch, B., Lee Shing, Y., &
981 Werkle-Bergner, M. (2020). Memory quality modulates the effect of aging on memory
982 consolidation during sleep: Reduced maintenance but intact gain. *NeuroImage*, 209.
983 <https://doi.org/10.1016/j.neuroimage.2019.116490>
- 984 Murrell, J., Ghetti, B., Cochran, E., Macias-Islas, M. A., Medina, L., Varpertian, A., ...
985 Ringman, J. M. (2006). The A431E mutation in PSEN1 causing Familial Alzheimer's
986 Disease originating in Jalisco State, Mexico: An additional fifteen families.
987 *Neurogenetics*, 7(4), 277–279. <https://doi.org/10.1007/s10048-006-0053-1>
- 988 Nakane, T., Nihashi, T., Kawai, H., & Naganawa, S. (2008). Visualization of neuromelanin in
989 the Substantia nigra and locus ceruleus at 1.5T using a 3D-gradient echo sequence with

- 990 magnetization transfer contrast. *Magnetic Resonance in Medical Sciences : MRMS : An*
991 *Official Journal of Japan Society of Magnetic Resonance in Medicine*, 7(4), 205–210.
992 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/19110515>
- 993 Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., ...
994 Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool
995 for mild cognitive impairment. *Journal of the American Geriatrics Society*, 53(4), 695–
996 699. <https://doi.org/10.1111/j.1532-5415.2005.53221.x>
- 997 O'Bryant, S. E., Waring, S. C., Cullum, C. M., Hall, J., Lacritz, L., Massman, P. J., ... Doody,
998 R. (2008). Staging dementia using clinical dementia rating scale sum of boxes scores: A
999 Texas Alzheimer's research consortium study. *Archives of Neurology*, 65(8), 1091–1095.
1000 <https://doi.org/10.1001/archneur.65.8.1091>
- 1001 O'Dell, T. J., Connor, S. A., Guglietta, R., & Nguyen, P. V. (2015). β -Adrenergic receptor
1002 signaling and modulation of long-term potentiation in the mammalian hippocampus.
1003 *Learning & Memory*, 22(9), 461–471. <https://doi.org/10.1101/lm.031088.113>
- 1004 Parker, J., Mozaffar, T., Messmore, A., Deignan, J. L., Kimonis, V. E., & Ringman, J. M.
1005 (2019). Homozygosity for the A431E mutation in PSEN1 presenting with a relatively
1006 aggressive phenotype. *Neuroscience Letters*, 699, 195–198.
1007 <https://doi.org/10.1016/j.neulet.2019.01.047>
- 1008 Penny, W., Friston, K., Ashburner, J., Kiebel, S., & Nichols, T. (2007). *Statistical Parametric*
1009 *Mapping: The Analysis of Functional Brain Images. Statistical Parametric Mapping:*
1010 *The Analysis of Functional Brain Images*. Elsevier Ltd. [https://doi.org/10.1016/B978-0-](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)
1011 [12-372560-8.X5000-1](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)
- 1012 Poe, G. R., Foote, S., Eschenko, O., Johansen, J. P., Bouret, S., Aston-Jones, G., ... Sara, S. J.
1013 (2020). Locus coeruleus: a new look at the blue spot. *Nature Reviews Neuroscience*, 1–
1014 16. <https://doi.org/10.1038/s41583-020-0360-9>
- 1015 Possin, K. L., Laluz, V. R., Alcantar, O. Z., Miller, B. L., & Kramer, J. H. (2011). Distinct

- 1016 neuroanatomical substrates and cognitive mechanisms of figure copy performance in
1017 Alzheimer's disease and behavioral variant frontotemporal dementia. *Neuropsychologia*,
1018 49(1), 43–48. <https://doi.org/10.1016/j.neuropsychologia.2010.10.026>
- 1019 Priovoulos, N., Jacobs, H. I. L., Ivanov, D., Uludag, K., Verhey, F. R. J., & Poser, B. A.
1020 (2017). High-resolution in vivo imaging of human locus coeruleus by magnetization
1021 transfer MRI at 3T and 7T. *NeuroImage*, 168, 127–136.
1022 <https://doi.org/10.1016/j.neuroimage.2017.07.045>
- 1023 Ringman, J. M. (2005). What the study of persons at risk for familial Alzheimer's disease can
1024 tell us about the earliest stages of the disorder: A review. In *Journal of Geriatric*
1025 *Psychiatry and Neurology* (Vol. 18, pp. 228–233). Sage PublicationsSage CA: Thousand
1026 Oaks, CA. <https://doi.org/10.1177/0891988705281878>
- 1027 Ringman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., ... Vinters, H. V.
1028 (2016). Neuropathology of Autosomal Dominant Alzheimer Disease in the National
1029 Alzheimer Coordinating Center Database. *Journal of Neuropathology & Experimental*
1030 *Neurology*, 75(3), 284–290. <https://doi.org/10.1093/jnen/nlv028>
- 1031 Rohlfing, T., Brandt, R., Menzel, R., & Maurer, C. R. (2004). Evaluation of atlas selection
1032 strategies for atlas-based image segmentation with application to confocal microscopy
1033 images of bee brains. *NeuroImage*, 21(4), 1428–1442.
1034 <https://doi.org/10.1016/j.neuroimage.2003.11.010>
- 1035 Rorabaugh, J. M., Chalermpananupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A.,
1036 Cohen, R. M., & Weinshenker, D. (2017). Chemogenetic locus coeruleus activation
1037 restores reversal learning in a rat model of Alzheimer's disease. *Brain*, 140(11), 3023–
1038 3038. <https://doi.org/10.1093/brain/awx232>
- 1039 Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., ... Bateman, R.
1040 J. (2014). Symptom onset in autosomal dominant Alzheimer disease: A systematic
1041 review and meta-analysis. *Neurology*, 83(3), 253–260.

- 1042 <https://doi.org/10.1212/WNL.0000000000000596>
- 1043 Sabuncu, M. R., Yeo, B. T. T., Van Leemput, K., Fischl, B., & Golland, P. (2010). A
1044 generative model for image segmentation based on label fusion. *IEEE Transactions on*
1045 *Medical Imaging*, 29(10), 1714–1729. <https://doi.org/10.1109/TMI.2010.2050897>
- 1046 Sara, S. J. (2009). The locus coeruleus and noradrenergic modulation of cognition. *Nature*
1047 *Reviews Neuroscience*, 10(3), 211–223. <https://doi.org/10.1038/nrn2573>
- 1048 Sasaki, M., Shibata, E., Tohyama, K., Takahashi, J., Otsuka, K., Tsuchiya, K., ... Sakai, A.
1049 (2006). Neuromelanin magnetic resonance imaging of locus ceruleus and substantia
1050 nigra in Parkinson's disease. *NeuroReport*, 17(11), 1215–1218.
1051 <https://doi.org/10.1097/01.wnr.0000227984.84927.a7>
- 1052 Satoh, A., & Iijima, K. M. (2019). Roles of tau pathology in the locus coeruleus (LC) in age-
1053 associated pathophysiology and Alzheimer's disease pathogenesis: Potential strategies to
1054 protect the LC against aging. *Brain Research*, 1702, 17–28.
1055 <https://doi.org/10.1016/J.BRAINRES.2017.12.027>
- 1056 Schoenberg, M. R., Dawson, K. A., Duff, K., Patton, D., Scott, J. G., & Adams, R. L. (2006).
1057 Test performance and classification statistics for the Rey Auditory Verbal Learning Test
1058 in selected clinical samples. *Archives of Clinical Neuropsychology*, 21(7), 693–703.
1059 <https://doi.org/10.1016/j.acn.2006.06.010>
- 1060 Snider, B. J., Norton, J., Coats, M. A., Chakraverty, S., Hou, C. E., Jervis, R., ... Morris, J. C.
1061 (2005). Novel presenilin 1 mutation (S170F) causing Alzheimer disease with lewy
1062 bodies in the third decade of life. *Archives of Neurology*, 62(12), 1821–1830.
1063 <https://doi.org/10.1001/archneur.62.12.1821>
- 1064 Stratmann, K., Heinsen, H., Korf, H. W., Del Turco, D., Ghebremedhin, E., Seidel, K., ...
1065 Rüb, U. (2016). Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal
1066 Pathology. *Brain Pathology*, 26(3), 371–386. <https://doi.org/10.1111/bpa.12289>
- 1067 Sun, W., Tang, Y., Qiao, Y., Ge, X., Mather, M., Ringman, J. M., & Shi, Y. (2020). A

- 1068 probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome
1069 imaging in Alzheimer's disease. *NeuroImage*, 223, 117301.
1070 <https://doi.org/10.1016/j.neuroimage.2020.117301>
- 1071 Takahashi, J., Shibata, T., Sasaki, M., Kudo, M., Yanezawa, H., Obara, S., ... Terayama, Y.
1072 (2015). Detection of changes in the locus coeruleus in patients with mild cognitive
1073 impairment and Alzheimer's disease: High-resolution fast spin-echo T1-weighted
1074 imaging. *Geriatrics and Gerontology International*, 15(3), 334–340.
1075 <https://doi.org/10.1111/ggi.12280>
- 1076 Takeuchi, T., Duzkiewicz, A. J., Sonneborn, A., Spooner, P. A., Yamasaki, M., Watanabe, M.,
1077 ... Morris, R. G. M. (2016). Locus coeruleus and dopaminergic consolidation of
1078 everyday memory. *Nature*, 537(7620), 357–362. <https://doi.org/10.1038/nature19325>
- 1079 Tanzi, R. E., & Bertram, L. (2005, February 25). Twenty years of the Alzheimer's disease
1080 amyloid hypothesis: A genetic perspective. *Cell*. Cell Press.
1081 <https://doi.org/10.1016/j.cell.2005.02.008>
- 1082 Teng, E. L., Hasegawa, K., Homma, A., Imai, Y., Larson, E., Graves, A., ... White, L. R.
1083 (1994). The Cognitive Abilities Screening Instrument (CASI): A Practical Test for Cross-
1084 Cultural Epidemiological Studies of Dementia. *International Psychogeriatrics*, 6(1), 45–
1085 58. <https://doi.org/10.1017/s1041610294001602>
- 1086 Theofilas, P., Dunlop, S., Heinsen, H., & Grinberg, L. T. (2015). Turning on the light within:
1087 Subcortical nuclei of the isodentritic core and their role in Alzheimer's disease
1088 pathogenesis. *Journal of Alzheimer's Disease*, 46(1), 17–34.
1089 <https://doi.org/10.3233/JAD-142682>
- 1090 Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P.,
1091 ... Grinberg, L. T. (2017). Locus coeruleus volume and cell population changes during
1092 Alzheimer's disease progression: A stereological study in human postmortem brains with
1093 potential implication for early-stage biomarker discovery. *Alzheimer's and Dementia*,

- 1094 13(3), 236–246. <https://doi.org/10.1016/j.jalz.2016.06.2362>
- 1095 Tombaugh, T. (2004). Trail Making Test A and B: Normative data stratified by age and
1096 education. *Archives of Clinical Neuropsychology*, 19(2), 203–214.
1097 [https://doi.org/10.1016/S0887-6177\(03\)00039-8](https://doi.org/10.1016/S0887-6177(03)00039-8)
- 1098 Tona, K. D., Keuken, M. C., de Rover, M., Lakke, E., Forstmann, B. U., Nieuwenhuis, S., &
1099 van Osch, M. J. P. (2017). In vivo visualization of the locus coeruleus in humans:
1100 Quantifying the test–retest reliability. *Brain Structure and Function*, 222(9), 4203–4217.
1101 <https://doi.org/10.1007/s00429-017-1464-5>
- 1102 Uematsu, A., Tan, B. Z., Ycu, E. A., Cuevas, J. S., Koivumaa, J., Junyent, F., ... Johansen, J.
1103 P. (2017). Modular organization of the brainstem noradrenaline system coordinates
1104 opposing learning states. *Nature Neuroscience*, 20(11), 1602–1611.
1105 <https://doi.org/10.1038/nn.4642>
- 1106 Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016, May 1). The genetic
1107 landscape of Alzheimer disease: Clinical implications and perspectives. *Genetics in*
1108 *Medicine*. Nature Publishing Group. <https://doi.org/10.1038/gim.2015.117>
- 1109 Wagatsuma, A., Okuyama, T., Sun, C., Smith, L. M., Abe, K., & Tonegawa, S. (2018). Locus
1110 coeruleus input to hippocampal CA3 drives single-trial learning of a novel context.
1111 *Proceedings of the National Academy of Sciences of the United States of America*,
1112 115(2), E310–E316. <https://doi.org/10.1073/pnas.1714082115>
- 1113 Wang, H., Suh, J. W., Das, S. R., Pluta, J. B., Craige, C., & Yushkevich, P. A. (2013). Multi-
1114 atlas segmentation with joint label fusion. *IEEE Transactions on Pattern Analysis and*
1115 *Machine Intelligence*, 35(3), 611–623. <https://doi.org/10.1109/TPAMI.2012.143>
- 1116 Wechsler, D. (1981). *WAIS-R manual: Wechsler Adult Intelligence Scale-Revised*. New York:
1117 Psychological Corporation.
- 1118 Wechsler, D. (1997). *WAIS-III: administration and scoring manual: Wechsler Adult*
1119 *Intelligence Scale* (3rd ed.). [San Antonio Tex]: Psychological Corporation.

- 1120 Weinshenker, D. (2018). Long road to ruin: Noradrenergic dysfunction in neurodegenerative
1121 disease. *Trends in Neurosciences*, *41*(4), 211–223.
1122 <https://doi.org/10.1016/j.tins.2018.01.010>
- 1123 World Health Organization. (2004). ICD-10 : international statistical classification of diseases
1124 and related health problems : tenth revision. World Health Organization.
- 1125 Ye, R., Rua, C., O’Callaghan, C., Jones, P. S., Hezemans, F. H., Kaalund, S. S., ... Rowe, J. B.
1126 (2021). An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field.
1127 *NeuroImage*, *225*, 117487. <https://doi.org/10.1016/j.neuroimage.2020.117487>
- 1128 Yescas, P., Huertas-Vazquez, A., Villarreal-Molina, M. T., Rasmussen, A., Tusié-Luna, M. T.,
1129 López, M., ... Alonso, M. E. (2006). Founder effect for the Ala431Glu mutation of the
1130 presenilin 1 gene causing early-onset Alzheimer’s disease in Mexican families.
1131 *Neurogenetics*, *7*(3), 195–200. <https://doi.org/10.1007/s10048-006-0043-3>
1132